Telix ProstACT Phase 3 Study Shows Positive Safety Results
Melbourne, Australia & Indianapolis, United States – March 10, 2026 Telix Pharmaceuticals has announced that Part 1 of the...
Phase 3 Clinical Trial
Advertisement
Johnson & Johnson Wins FDA Approval for Tecvayli–Darzalex Myeloma Therapy
HORSHAM, Pennsylvania – March 5, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration has approved...
CG Oncology Advances Phase 3 Timeline for NMIBC Trial
IRVINE, California | January 9, 2026 — CG Oncology, Inc., a late-stage clinical biopharmaceutical company, has announced an accelerated...
Ultragenyx Reports Phase 3 Setrusumab Results in OI
NOVATO, Calif., December 29, 2025 — Ultragenyx Pharmaceutical announced results from its Phase 3 Orbit and Cosmic clinical trials...
SELLAS Updates Phase 3 REGAL Trial in AML
NEW YORK, December 29, 2025 — SELLAS Life Sciences Group has provided a key update on its pivotal Phase...
Advertisements
MAIA Board Financing Reinforces Confidence in Phase 3 Cancer Drug
CHICAGO, USA | December 24, 2025 — MAIA Biotechnology, a clinical-stage biopharmaceutical company focused on targeted immuno-oncology, announced that...
Telix Reports Phase 3 Success and FDA Progress in Dx
MELBOURNE, Australia; INDIANAPOLIS, United States — December 22, 2025 — Telix Pharmaceuticals Limited has reported a major precision medicine...
BioCryst Acquires Astria Therapeutics to Expand HAE Pipeline
BOSTON – October 14, 2025 – BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Astria Therapeutics, Inc. (NASDAQ: ATXS) announced a...
Bristol Myers Squibb’s Iberdomide Shows Strong Phase 3 Results in Multiple Myeloma
Princeton, N.J., September 22, 2025 – Bristol Myers Squibb (BMS) announced that its investigational cereblon E3 ligase modulator (CELMoD™)...
Advertisement
